TrialThe oncologist2023

Activity of Anlotinib in the Second-Line Therapy of Metastatic Gastrointestinal Stromal Tumors: A Prospective, Multicenter, In Vitro Study.

Yongjian Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.